CRSP peer analysis
CRISPR Therapeutics (CRSP) against its competitors: price, today's move, 1-year return and market value side by side.
CRSP and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BEAM Beam Therapeutics | $25.86 | -5.03% | 8.66% | $2.81B |
| DNA Ginkgo | $9.84 | -12.22% | -18.07% | – |
| DTIL Precision BioSciences | $7.06 | -5.11% | -18.00% | $194.87M |
| EDIT Editas Medicine | $2.57 | -3.75% | -14.62% | $410.06M |
| MGX Metagenomi Therapeutics | $0.78 | -6.01% | -68.02% | – |
| NTLA Intellia | $11.67 | -6.42% | -4.85% | $1.75B |
| RGNX REGENXBIO | $7.20 | -2.83% | -43.84% | $475.29M |
| CRSP CRISPR Therapeutics | $49.57 | -3.60% | -18.87% | $4.97B |
- CRSP's peers: BEAM (Beam Therapeutics), DNA (Ginkgo), DTIL (Precision BioSciences), EDIT (Editas Medicine), MGX (Metagenomi Therapeutics), NTLA (Intellia), RGNX (REGENXBIO).
Updated 2026-11-03 02:05 UTC